Cytosponge Protocol

Overview

About this study

Whether the cytosponge will be a useful non-invasive tool in evaluating patients with eosinophilic esophagitis?

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients between the ages of 18 and 65 with eosinophilic esophagitis including lactating or pregnant women undergoing clinically indicated endoscopy and esophageal biopsy.

Exclusion Criteria:

  • Patients for whom clinically indicated endoscopy is not safe. Patients who have small caliber esophagus, an esophageal stricture that will not permit passage of the gelatin capsule or are unable to swallow the capsule.
  • Vulnerable populations, such as those with diminished mental acuity
  • Patients with known Lidocaine/Acetylcysteine allergies
  • Patients who have taken any antithrombotic medications within 10 days of the procedure

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

David Katzka, M.D.

Closed for enrollment

Contact information:

Crystal Lavey CCRP

(507) 538-1361

Lavey.Crystal@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20112055

Mayo Clinic Footer